TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access TB Alliance
BALI, Indonesia (November 11, 2024)—TB Alliance is honored to join today’s High-Level Meeting hosted by the Indonesian Ministry of Health.
NEW YORK (December 9, 2024)—TB Alliance welcomes Srishti Gupta, MD, MPP, MPhil, and Akshay Vaishnaw, MB, BCh, PhD, FRCP, to
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health
New York (October 7, 2024) – TB Alliance is proud to announce a $7.35 million award through the U.S. Department
MANILA (September 3, 2024) – A delegation of experts from Brazil’s National TB Program visited Manila recently to collaborate with
NEW YORK (August 21, 2024) – In July 2024, a Phase 2 proof-of-concept study was initiated to explore the use
NEW YORK (August, 15, 2024)—TB Alliance is honored to appoint Ann Taylor, MD to its Board of Directors. Welcoming Dr.
MANILA (25 March 2024)—TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding
CANBERRA (25 March 2024)—The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17
